Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
Amar Ali, Steve Baín, Debbie Hicks, et al.
Diabetes Therapy (2019) Vol. 10, Iss. 5, pp. 1595-1622
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Drug Therapy in Obesity: A Review of Current and Emerging Treatments
David M. Williams, Asif Nawaz, Marc Evans
Diabetes Therapy (2020) Vol. 11, Iss. 6, pp. 1199-1216
Open Access | Times Cited: 167
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
Melanie J. Davies, Heinz Drexel, François R. Jornayvaz, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 44
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
Bains Jasleen, Gupta K Vishal, Malepati Sameera, et al.
Cureus (2023)
Open Access | Times Cited: 37
A comprehensive review of small-molecule drugs for the treatment of type 2 diabetes mellitus: Synthetic approaches and clinical applications
Yuanyuan Guo, Jingyi Zhang, Jinfeng Sun, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116185-116185
Closed Access | Times Cited: 14
Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
David M. Williams, Asif Nawaz, Marc Evans
Diabetes Therapy (2019) Vol. 11, Iss. 2, pp. 369-386
Open Access | Times Cited: 59
SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review
Samuel Seidu, Vicki Alabraba, Sarah Davies, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 5, pp. 1099-1124
Open Access | Times Cited: 8
The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials
Leonardo Buttice, Maryam Ghani, Janahan Suthakar, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 7, pp. 2706-2721
Open Access | Times Cited: 8
The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus
Bertram Pitt, Philippe Gabríel Steg, Lawrence A. Leiter, et al.
Cardiovascular Drugs and Therapy (2021) Vol. 36, Iss. 3, pp. 561-567
Open Access | Times Cited: 30
Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes
Mazhar Hussain, Asim Elahi, Abid Hussain, et al.
Journal of Diabetes Research (2021) Vol. 2021, pp. 1-5
Open Access | Times Cited: 28
A Critical View over the Newest Antidiabetic Molecules in Light of Efficacy—A Systematic Review and Meta-Analysis
Teodor Salmen, Liviu Ionuț Șerbănoiu, Cristina Bică, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9760-9760
Open Access | Times Cited: 13
Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?
Jennifer Snaith, D. Jane Holmes‐Walker, Jerry R. Greenfield
Trends in Endocrinology and Metabolism (2019) Vol. 31, Iss. 2, pp. 150-164
Closed Access | Times Cited: 34
SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
David C. Wheeler, June James, Dipesh Patel, et al.
Diabetes Therapy (2020) Vol. 11, Iss. 12, pp. 2757-2774
Open Access | Times Cited: 31
Mitochondrial Ca2+, redox environment and ROS emission in heart failure: Two sides of the same coin?
Sonia Cortassa, Magdalena Juhaszova, Miguel A. Aon, et al.
Journal of Molecular and Cellular Cardiology (2020) Vol. 151, pp. 113-125
Open Access | Times Cited: 31
SGLT2 inhibitors – a potential treatment for Alport syndrome
Holly Mabillard, John A. Sayer
Clinical Science (2020) Vol. 134, Iss. 4, pp. 379-388
Closed Access | Times Cited: 28
The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review
John Wilding, Marc Evans, Kevin Fernando, et al.
Diabetes Therapy (2022) Vol. 13, Iss. 5, pp. 847-872
Open Access | Times Cited: 17
Exploring the causal factor effects of hypothyroidism on ischemic stroke: a two-sample Mendelian randomization study
Yi Tian, Xiao Shi, Jing Wen Shui, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 3
Congestive Heart Failure
Mukesh Nandave
(2024), pp. 355-394
Closed Access | Times Cited: 3
Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review
Shaline Rao
Advances in Therapy (2021) Vol. 39, Iss. 2, pp. 845-861
Open Access | Times Cited: 23
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
Munteanu Madalina Andreea, Swarnkar Surabhi, Răzvan-Ionuț Popescu, et al.
Medicina (2023) Vol. 59, Iss. 4, pp. 742-742
Open Access | Times Cited: 9
A look to the future in non‐alcoholic fatty liver disease: Are glucagon‐like peptide‐1 analogues or sodium‐glucose co‐transporter‐2 inhibitors the answer?
Rebecca Vincent, David M. Williams, Marc Evans
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. 12, pp. 2227-2240
Open Access | Times Cited: 18
Metainflammation in COVID-19
Mojtaba Bakhtiari, Kamyar Asadipooya
Endocrine Metabolic & Immune Disorders - Drug Targets (2022) Vol. 22, Iss. 12, pp. 1154-1166
Closed Access | Times Cited: 11
Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials
David M. Williams, Marc Evans
Diabetes Therapy (2020) Vol. 11, Iss. 9, pp. 1925-1934
Open Access | Times Cited: 16
Cardiovascular protection significantly depends on HbA1c improvement with GLP-1RAs but not with SGLT2 is in type 2 diabetes: A narrative review
André Scheen
Diabetes & Metabolism (2023) Vol. 50, Iss. 2, pp. 101508-101508
Closed Access | Times Cited: 4
Association between fasting insulin and C-reactive protein among adults without diabetes using a two-part model: NHANES 2005–2010
Amanda L. Missel, Laura R. Saslow, Dina Hafez, et al.
Diabetology & Metabolic Syndrome (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 10
Crosstalk between Sodium–Glucose Cotransporter Inhibitors and Sodium–Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases
Al-Anood Al-Shamasi, Rozina Elkaffash, Meram Mohamed, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 23, pp. 12677-12677
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top